Overview A Study of CDI-31244: A Novel NNI in HV and HCV Infected Subjects Status: Completed Trial end date: 2017-04-01 Target enrollment: Participant gender: Summary This is a First in Human study of orally administered CDI-31244, a non-nucleoside inhibitor (NNI) in healthy volunteers and HCV infected individuals Phase: Phase 1 Details Lead Sponsor: Cocrystal Pharma, Inc.